Petros Historical Balance Sheet

PTPI Stock

USD 0.29 0.02 7.41%

Trend analysis of Petros Pharmaceuticals balance sheet accounts such as Accounts Payable of 2.6 M, Other Assets of 9.4 M, Net Receivables of 2.6 M or Inventory of 1.8 M provides information on Petros Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Petros Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Petros Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Petros Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Petros Pharmaceuticals is a good buy for the upcoming year.

Petros Pharmaceuticals Inventory

1.79 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.

About Petros Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Petros Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Petros Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Petros Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Petros currently owns. An asset can also be divided into two categories, current and non-current.

Petros Pharmaceuticals Balance Sheet Chart

As of now, Petros Pharmaceuticals' Net Receivables is decreasing as compared to previous years. The Petros Pharmaceuticals' current Inventory is estimated to increase to about 1.8 M, while Total Current Liabilities is projected to decrease to under 10.2 M.

Other Current Liab Total Current Liabilities Other Liab Accounts Payable

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Petros Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Petros Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Petros Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Petros Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Petros Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Petros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.As of now, Petros Pharmaceuticals' Net Receivables is decreasing as compared to previous years. The Petros Pharmaceuticals' current Inventory is estimated to increase to about 1.8 M, while Total Current Liabilities is projected to decrease to under 10.2 M.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	31.0M	7.1M	10.8M	10.2M
Other Current Liabilities	26.4M	4.0M	7.8M	10.7M

Total Current Liabilities Other Current Liab

Petros Pharmaceuticals balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total
Other Current Liab		0.32	0.61	0.16	0.0	0.6	0.22	0.38	-0.18	0.47	0.8	-0.48	0.65	-0.52	0.53	0.56	0.01	-0.56	0.55	0.25	0.84	0.48	0.55	-0.29	-0.05	-0.42
Total Current Liabilities	0.32		0.47	-0.84	0.82	0.14	-0.68	0.81	0.56	-0.34	-0.2	0.19	0.9	0.5	-0.41	-0.45	0.89	0.47	-0.49	0.97	0.6	0.05	-0.49	0.74	-0.91	0.06
Other Liab	0.61	0.47		-0.16	0.11	0.57	0.1	0.85	-0.09	0.16	0.26	-0.08	0.55	0.0	-0.06	0.35	0.44	-0.09	0.12	0.37	0.6	0.38	0.12	-0.07	-0.17	0.33
Net Tangible Assets	0.16	-0.84	-0.16		-0.95	0.35	0.92	-0.61	-0.85	0.7	0.67	-0.21	-0.55	-0.87	0.79	0.83	-0.96	-0.86	0.88	-0.88	-0.11	0.29	0.88	-0.97	0.94	-0.36
Retained Earnings	0.0	0.82	0.11	-0.95		-0.43	-0.95	0.51	0.93	-0.7	-0.54	-0.07	0.58	0.78	-0.68	-0.79	0.89	0.79	-0.81	0.88	0.17	-0.24	-0.81	0.94	-0.94	0.21
Accounts Payable	0.6	0.14	0.57	0.35	-0.43		0.57	0.38	-0.72	0.63	0.69	0.31	0.46	-0.64	0.63	0.74	-0.17	-0.69	0.69	0.04	0.75	0.55	0.69	-0.51	0.18	-0.38
Other Assets	0.22	-0.68	0.1	0.92	-0.95	0.57		-0.35	-0.94	0.78	0.67	-0.01	-0.4	-0.83	0.72	0.87	-0.81	-0.87	0.88	-0.79	0.03	0.45	0.88	-0.96	0.91	-0.24
Net Receivables	0.38	0.81	0.85	-0.61	0.51	0.38	-0.35		0.27	-0.15	-0.09	0.19	0.74	0.38	-0.39	-0.1	0.8	0.31	-0.29	0.75	0.58	0.1	-0.29	0.42	-0.63	0.39
Inventory	-0.18	0.56	-0.09	-0.85	0.93	-0.72	-0.94	0.27		-0.76	-0.65	-0.24	0.27	0.84	-0.76	-0.86	0.75	0.86	-0.87	0.66	-0.15	-0.42	-0.87	0.9	-0.78	0.34
Other Current Assets	0.47	-0.34	0.16	0.7	-0.7	0.63	0.78	-0.15	-0.76		0.84	-0.02	-0.03	-0.82	0.69	0.7	-0.6	-0.85	0.86	-0.47	0.27	0.15	0.86	-0.74	0.58	-0.34
Total Current Assets	0.8	-0.2	0.26	0.67	-0.54	0.69	0.67	-0.09	-0.65	0.84		-0.33	0.22	-0.92	0.88	0.83	-0.55	-0.93	0.92	-0.28	0.59	0.41	0.92	-0.73	0.45	-0.61
Common Stock	-0.48	0.19	-0.08	-0.21	-0.07	0.31	-0.01	0.19	-0.24	-0.02	-0.33		0.08	0.17	-0.15	-0.17	0.16	0.17	-0.17	0.15	-0.01	-0.07	-0.17	0.19	-0.17	0.06
Total Assets	0.65	0.9	0.55	-0.55	0.58	0.46	-0.4	0.74	0.27	-0.03	0.22	0.08		0.08	0.02	-0.07	0.63	0.06	-0.08	0.86	0.88	0.25	-0.08	0.42	-0.73	-0.27
Short Long Term Debt Total	-0.52	0.5	0.0	-0.87	0.78	-0.64	-0.83	0.38	0.84	-0.82	-0.92	0.17	0.08		-0.97	-0.89	0.81	0.99	-0.99	0.55	-0.35	-0.42	-0.99	0.88	-0.68	0.67
Total Stockholder Equity	0.53	-0.41	-0.06	0.79	-0.68	0.63	0.72	-0.39	-0.76	0.69	0.88	-0.15	0.02	-0.97		0.83	-0.76	-0.95	0.93	-0.43	0.44	0.5	0.93	-0.79	0.57	-0.81
Property Plant And Equipment Net	0.56	-0.45	0.35	0.83	-0.79	0.74	0.87	-0.1	-0.86	0.7	0.83	-0.17	-0.07	-0.89	0.83		-0.66	-0.91	0.93	-0.51	0.39	0.56	0.93	-0.92	0.7	-0.37
Current Deferred Revenue	0.01	0.89	0.44	-0.96	0.89	-0.17	-0.81	0.8	0.75	-0.6	-0.55	0.16	0.63	0.81	-0.76	-0.66		0.78	-0.78	0.9	0.24	-0.17	-0.78	0.87	-0.9	0.46
Net Debt	-0.56	0.47	-0.09	-0.86	0.79	-0.69	-0.87	0.31	0.86	-0.85	-0.93	0.17	0.06	0.99	-0.95	-0.91	0.78		-1.0	0.55	-0.38	-0.49	-1.0	0.9	-0.7	0.61
Cash	0.55	-0.49	0.12	0.88	-0.81	0.69	0.88	-0.29	-0.87	0.86	0.92	-0.17	-0.08	-0.99	0.93	0.93	-0.78	-1.0		-0.56	0.36	0.46	1.0	-0.92	0.71	-0.56
Non Current Assets Total	0.25	0.97	0.37	-0.88	0.88	0.04	-0.79	0.75	0.66	-0.47	-0.28	0.15	0.86	0.55	-0.43	-0.51	0.9	0.55	-0.56		0.55	-0.06	-0.56	0.8	-0.97	0.05
Non Currrent Assets Other	0.84	0.6	0.6	-0.11	0.17	0.75	0.03	0.58	-0.15	0.27	0.59	-0.01	0.88	-0.35	0.44	0.39	0.24	-0.38	0.36	0.55		0.52	0.36	-0.04	-0.34	-0.49
Long Term Debt	0.48	0.05	0.38	0.29	-0.24	0.55	0.45	0.1	-0.42	0.15	0.41	-0.07	0.25	-0.42	0.5	0.56	-0.17	-0.49	0.46	-0.06	0.52		0.46	-0.39	0.26	-0.42
Cash And Short Term Investments	0.55	-0.49	0.12	0.88	-0.81	0.69	0.88	-0.29	-0.87	0.86	0.92	-0.17	-0.08	-0.99	0.93	0.93	-0.78	-1.0	1.0	-0.56	0.36	0.46		-0.92	0.71	-0.56
Common Stock Total Equity	-0.29	0.74	-0.07	-0.97	0.94	-0.51	-0.96	0.42	0.9	-0.74	-0.73	0.19	0.42	0.88	-0.79	-0.92	0.87	0.9	-0.92	0.8	-0.04	-0.39	-0.92		-0.91	0.3
Common Stock Shares Outstanding	-0.05	-0.91	-0.17	0.94	-0.94	0.18	0.91	-0.63	-0.78	0.58	0.45	-0.17	-0.73	-0.68	0.57	0.7	-0.9	-0.7	0.71	-0.97	-0.34	0.26	0.71	-0.91		-0.11
Non Current Liabilities Total	-0.42	0.06	0.33	-0.36	0.21	-0.38	-0.24	0.39	0.34	-0.34	-0.61	0.06	-0.27	0.67	-0.81	-0.37	0.46	0.61	-0.56	0.05	-0.49	-0.42	-0.56	0.3	-0.11

Click cells to compare fundamentals

Petros Pharmaceuticals Account Relationship Matchups

Petros Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	453.1K	29.1M	26.4M	4.0M	7.8M	10.7M
Total Current Liabilities	41.1M	41.9M	31.0M	7.1M	10.8M	10.2M
Retained Earnings	(41.1M)	(61.7M)	(70.7M)	(90.7M)	(98.9M)	(93.9M)
Accounts Payable	3.8M	5.6M	4.6M	1.8M	1.7M	2.6M
Net Receivables	3.8M	5.2M	2.5M	2.1M	2.2M	2.6M
Inventory	2.2M	760.5K	519.6K	1.8M	1.6M	1.8M
Other Current Assets	1.9M	2.9M	3.1M	1.3M	3.2M	2.6M
Total Current Assets	12.1M	25.9M	30.5M	14.7M	20.4M	21.9M
Common Stock	29.1M	971.0	2.1K	208.0	298.0	283.1

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:

How To Invest In Petros

Details

Is Petros Stock a good investment?

Details

What is Petros Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.80)

Revenue Per Share

0.99

Quarterly Revenue Growth

(0.29)

Return On Assets

(0.31)

Return On Equity

(0.64)

The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Petros Historical Balance Sheet

Petros Pharmaceuticals Inventory

1.79 Million

About Petros Balance Sheet Analysis

Petros Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Petros Pharmaceuticals balance sheet Correlations

Petros Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Petros Pharmaceuticals balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Total Current Liabilities
Common Stock Shares Outstanding	+ 0.94	Net Tangible Assets
Common Stock Total Equity	+ 0.94	Retained Earnings
Inventory	+ 0.93	Retained Earnings

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Short Long Term Debt Total
Cash	- 0.99	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.97	Non Current Assets Total
Total Stockholder Equity	- 0.97	Short Long Term Debt Total